A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/015 (2006.01)
Patent
CA 2582455
The invention relates to novel vaccine regimens in which specific prime/boost regimens are applied using low-neutralized recombinant adenoviral vectors harboring nucleic acids encoding antigens from Plasmodium falciparum and purified recombinant protein vaccines such as RTS,S, in the context of appropriate adjuvants.
L'invention concerne de nouvelles stratégies de vaccination, dans lesquelles des stratégies du type primo-immunisation/rappel ("prime/boost") spécifiques sont appliquées à l'aide de vecteurs adénoviraux recombinés faiblement neutralisés, qui contiennent des acides nucléiques codant pour des antigènes de Plasmodium falciparum; et des vaccins à base de protéines recombinées purifiées telles que RTS,S, qui comprennent des adjuvants appropriés.
Cohen Joseph D.
Dubois Patrice M.
Goudsmit Jaap
Heppner Donald
Pau Maria Grazia
Borden Ladner Gervais Llp
Crucell Holland B.v.
Glaxosmithkline Biologicals S.a.
On Behalf Of The Walter Reed Army Institute Of Research The Government Of The United States As Represented By The Secret
LandOfFree
Malaria prime/boost vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Malaria prime/boost vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Malaria prime/boost vaccines will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1690889